Mr. Steven Theriault reports

CYTOPHAGE ANNOUNCES THE COMMERCIALIZATION OF OVAPHAGE IN CANADA THROUGH W.L.T. DISTRIBUTORS INC.

WLT Distributors Inc. has agreed to distribute OvaPhage across Canada for Cytophage Technologies Ltd. OvaPhage is a bacteriophage product for eggs designed to reduce salmonella load on egg shells, improving food safety and decreasing reliance on harsh chemical cleaning solutions.

This announcement follows Cytophage's recent receipt of Health Canada's Letter of No Objection (LONO) for the sale of OvaPhage. The LONO represents a key regulatory milestone for Cytophage and marks one of the first commercial bacteriophage products of its kind that will be available for sale in Canada.

"Cytophage is excited to have WLT Distributors on board to sell OvaPhage in Canada," said Dr. Steven Theriault, chief executive officer of Cytophage Technologies. "Our strength lies in developing scientifically advanced bacteriophage solutions. WLT Distributors bring decades of market knowledge, trusted relationships and on-the-ground expertise to help farmers adopt novel products that improve animal health and production efficiency. It's an ideal partnership. WLT provides efficient, cost-effective marketing and distribution services for agricultural and feed products, sharing Cytophage's vision of improving food safety and sustainability through leading-edge technologies."

Through significant work in the Cytophage laboratories and in collaboration with Canadian egg producers, the company is now ready to move forward with the commercialization and distribution of OvaPhage. As Cytophage completes work on packaging and labelling, WLT has identified early adopters willing to try this newly commercialized product.

"We have been following Cytophage's progress from R&D to commercialization and are thrilled to work with their team on sales and distribution. Given the challenges our industry faces today, it is critical we use innovative products that are both sustainable now and adaptable well into the future," said James Hokanson, chief operating officer of WLT.

According to Statistics Canada, the egg industry in Canada produced over 915 million dozen eggs in 2024. The company is looking forward to working with WLT to prepare OvaPhage for the market, ensuring the product meets the needs of prospective customers. Together, Cytophage and WLT aim to make OvaPhage broadly accessible to egg producers across Canada, contributing to sustainable food production in poultry operations.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR).

The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.